Aptevo Therapeutics Inc - APVO STOCK NEWS

Alligator Bioscience and Aptevo Therapeutics (NASDAQ: APVO) announced the publication of a significant article in Nature Communications regarding the mechanism of action of their 4-1BB targeting bispecific antibodies. The research, led by professor Ignacio Melero, reveals that bispecific antibodies like ALG.APV-527 induce a stronger immune response when they link co-stimulation directly to tumor cells. This publication validates the design of ALG.APV-527, which is advancing into Phase I clinical development and presents promising potential for cancer immunotherapy.

Aptevo Therapeutics (NASDAQ:APVO) provided a clinical update on its Phase 1b Expansion trial for APVO436 aimed at treating acute myeloid leukemia (AML). Preliminary results indicate one complete remission in a high-risk AML patient after combining chemotherapy with APVO436. Notably, this treatment exhibited a favorable safety profile, with no apparent toxicity. The trial's goal is to enhance remission quality by reducing measurable residual disease (MRD). Achieving MRD negativity is linked to improved survival rates in AML patients.

Aptevo Therapeutics (NASDAQ:APVO) announced the presentation of two abstracts at the 63rd American Society of Hematology Annual Meeting from December 11-14, 2021. The first abstract focuses on the CD3xCD123 Bispecific Antibody APVO436 for patients with relapsed/refractory AML or MDS, discussing tolerability and anti-neoplastic activity. The second abstract addresses the risk of Cytokine Release Syndrome in the same patient group. Both presentations will take place on December 13, 2021, from 6:00 PM-8:00 PM.

Aptevo Therapeutics reported its financial results for Q3 2021, highlighting a cash position of $53.4 million and a net loss of $7.0 million, or $1.43 per share. Royalty revenue from Pfizer's RUXIENCE was $3.1 million. The company initiated the expansion phase of its Phase 1B clinical trial for APVO436 in acute myeloid leukemia. Research and development expenses decreased slightly to $4.4 million, while general and administrative expenses rose to $3.5 million. Aptevo continues to progress with the ADAPTIR and ADAPTIR-FLEX platforms in various industry forums.

Alligator Bioscience and Aptevo Therapeutics announced the presentation of preclinical data for ALG.APV-527, a bispecific antibody targeting 4-1BB and tumor antigen 5T4, at the SITC Annual Meeting on November 13, 2021. The data suggest potential efficacy in eliciting antitumor responses with minimized systemic activation. The poster outlines a dual expression mechanism supporting clinical protocols and demonstrates enhanced immune-mediated tumor cell killing. This advancement supports the molecule's progression to a phase I clinical trial, indicating a promising future for treating 5T4-expressing solid tumors.

Aptevo Therapeutics (APVO) presented promising preclinical data on its bispecific antibody APVO603 at the SITC 2021 Annual Meeting. The data highlights APVO603's effectiveness in enhancing tumor cell lysis when combined with a bispecific T-cell engager. This dual 4-1BB and OX40 targeting approach may improve T cell responses against solid tumors while minimizing regulatory T cell suppression. CEO Marvin White expressed optimism about the results and the ongoing development of APVO603, which aims to deliver robust anti-tumor responses.

Aptevo Therapeutics (NASDAQ:APVO) will present clinical data on its leukemia drug candidate APVO436 at the 2nd Virtual Congress on Controversies in Leukemias on October 28-29, 2021. The presentation highlights findings from a Phase 1B clinical study involving 46 adult patients with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The data shows that APVO436 is generally well-tolerated and displays preliminary efficacy, underscoring its potential as a therapeutic option for patients in urgent need.

Aptevo Therapeutics Inc. (NASDAQ:APVO) announced that its research on APVO436, a bispecific antibody for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), has been published in Cancers. The study indicated that only 21.7% of 46 patients treated with APVO436 developed cytokine release syndrome (CRS), a common side effect of such therapies. The severe CRS cases were low at 8.7%. This promising data highlights APVO436 as a potential new treatment option for patients with these challenging blood cancers.

Aptevo Therapeutics announced that its lead candidate, APVO436, showed clinical activity and an acceptable safety profile for treating adults with myelodysplastic syndrome (MDS). The article published in Frontiers in Aging discusses the potential of bispecific antibodies to target both MDS clones and immunosuppressive cells, crucial for high-risk MDS patients. In a study, APVO436 induced complete remissions in 3 out of 6 evaluable high-risk MDS patients, suggesting its promise as a new anti-MDS drug candidate.